EMA Authorised: Arixtra (fondaparinux sodium) — Viatris Healthcare Limited

View source ↗

Summary

The EMA authorised Arixtra (fondaparinux sodium) by Viatris Healthcare Limited for thromboembolic conditions including venous thrombosis, pulmonary embolism, my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Pulmonary Embolism
• Unstable Angina
• Venous Thrombosis

Drugs mentioned

• ARIXTRA (fondaparinux sodium)

Snippet

Status: Authorised. Therapeutic area: Venous Thrombosis;Pulmonary Embolism;Myocardial Infarction;Angina, Unstable. MAH: Viatris Healthcare Limited. Decision date: 28/01/2026